Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07463976 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway

Study acronym: TITLE CLL
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Jul 2026 to Dec 2026
    • Study description expanded, about 6 words
    • Eligibility criteria expanded, about 2 words
  2. Minor Site contact updatedv2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will use surveys within primary and secondary care to explore referral patterns and healthcare professional (HCP) decision-making and advice for haematological malignancies, identify inequalities, and establish best practice for CLL referrals and specialist support. The project will allow us to understand and 'map' variations in practice across the West Midlands region with regard to referrals for CLL from primary care physicians to haematology services in secondary care. Specific objectives are to: 1. Identify service variations by using surveys to assess differences in CLL service provision across primary and secondary care in the West Midlands 2. Investigate service variations by describing the key characteristics of responding primary care practices (practice size, number of GPs, Integrated Care Board (ICB) locality, deprivation quartile) 3. Propose strategies to improve equity that will enhanced patient outcomes and reduce inequalities in care for CLL patients, aiming to ensure consistent standards for referral and management across different care settings.
Trial Details
NCT Number NCT07463976
Lead Sponsor The Royal Wolverhampton Hospitals NHS Trust
Collaborators: AstraZeneca
Conditions
(from sponsor)
Chronic Lymphocytic Leukemia, Haematological Malignancy
Related terms Hematologic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov